arrow
G

Gerhard Krönke

charite-universitaetsmedizin berlin
H指数:59
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial

CD19 CAR T细胞疗法治疗难治性血清阳性类风湿关节炎:一项1期临床试验

2026-08-270
PRE
Effect of apremilast on entheseal bone damage in psoriasis patients at risk of developing psoriatic arthritis - data from the prospective, interventional EPOS study

阿普米拉斯特对处于银屑病关节炎发展风险中的银屑病患者附着点骨骼损伤的影响——来自前瞻性、干预性EPOS研究的数据

2026-08-080
OAAI
Daratumumab in systemic lupus erythematosus: a single-arm phase 2 trial

Daratumumab治疗系统性红斑狼疮: 一项单臂2期试验

2026-02-030
OAAI
Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation

肠道菌群衍生的腐胺介导巨噬细胞免疫代谢重编程调控结肠炎症

2025-09-300
OAAI
Lupus nephritis and U1-RNP-antibodies are associated with low bone mineral density and osteoporosis in patients with systemic lupus erythematosus: baseline findings in a sub-cohort of patients with inflammatory rheumatic diseases

系统性红斑狼疮患者的狼疮肾炎和U1-RNP抗体与低骨矿物质密度和骨质疏松症相关:一项炎症性风湿病患者的亚群队列基线研究

2025-08-290
OA
Deep learning-based image analysis in muscle histopathology using photo-realistic synthetic data

使用照片般逼真的合成数据在肌肉组织病理学中进行基于深度学习的图像分析

2025-03-060
OAAI
Anti-CD19 CAR T cell therapy induces antibody seroconversion and complete B cell depletion in the bone marrow of a therapy- refractory patient with ANCA associated vasculitis-

抗CD19 CAR T细胞疗法诱导一例对疗法耐药的ANCA相关血管炎患者的骨髓中抗体血清转化及B细胞完全耗竭。

2025-03-011
PRE
Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders

成功产生完全人的第二代anti-CD19 CAR T细胞,用于各种自身免疫性疾病患者的临床

2025-02-012
OAAI
Baricitinib Dose Reduction in Patients With Rheumatoid Arthritis Achieving Sustained Disease Control: Final Results From the RA-BEYOND Study

巴瑞替尼剂量递减在达到持续疾病控制的类风湿关节炎患者中的应用:RA-BEYOND研究最终结果

2025-01-150
PRE
Metabolic profiling of single cells by exploiting NADH and FAD fluorescence via flow cytometry

通过流式细胞术利用NADH和FAD荧光对单细胞进行代谢分析

2024-09-010
OAAI